1. Home
  2. SNGX vs ABP Comparison

SNGX vs ABP Comparison

Compare SNGX & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.10

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

ABP

Abpro Holdings Inc

HOLD

Current Price

$0.70

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
ABP
Founded
1987
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4M
12.5M
IPO Year
1987
N/A

Fundamental Metrics

Financial Performance
Metric
SNGX
ABP
Price
$1.10
$0.70
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$6.00
N/A
AVG Volume (30 Days)
179.6K
4.1M
Earning Date
03-20-2026
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.00
52 Week Low
$1.02
$0.70
52 Week High
$6.23
$34.65

Technical Indicators

Market Signals
Indicator
SNGX
ABP
Relative Strength Index (RSI) 35.32 20.22
Support Level $1.04 $1.44
Resistance Level $1.16 $2.89
Average True Range (ATR) 0.08 0.37
MACD -0.01 -0.04
Stochastic Oscillator 17.95 0.84

Price Performance

Historical Comparison
SNGX
ABP

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About ABP Abpro Holdings Inc

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: